All about Jakob Lindberg - Zip.news

Sök - Finansinspektionen

Valberedningen föreslår omval av styrelseledamöterna, Behshad Sheldon, Fredrik Tiberg, 26 mars 2020 — Resultaten från HORIZON-studien stärker Oncopeptides uppfattning att melflufen kan spela en viktig Jakob Lindberg, VD för Oncopeptides. 9 mars 2021 — Jakob Lindberg (CSO för Oncopeptides) avser i samband med Nyemissionen avyttra 100 000 befintliga aktier i Bolaget till samma pris som 30 mars 2021 — STOCKHOLM (Nyhetsbyrån Direkt) Valberedningen i forskningsbolaget Camurus har föreslagit att Jakob Lindberg, Oncopeptides Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, 30 mars 2021 — STOCKHOLM (Nyhetsbyrån Direkt) Valberedningen i forskningsbolaget Camurus har föreslagit att Jakob Lindberg, Oncopeptides Det tar oss ett steg närmare att göra Ygalo® tillgängligt för patienter med multipelt myelom i sen fas" säger Jakob Lindberg, VD för Oncopeptides. Om Ygalo® Jakob-Lindberg-VD-Oncopeptides-fj. Publicerat den 19 augusti, 2019 vid 1000 × 774 under Framtidens japanska ledare – i Stockholm! Kommentarer är stängda 26 maj 2020 — Vd Jakob Lindberg om Oncopeptides senaste rapport.

Jakob lindberg oncopeptides

See our latest analysis for Oncopeptides Founder of Cellectricon AB, Stig Anders Jakob Lindberg currently is Chief Scientific Officer at Oncopeptides AB and Deputy Director at Oncopeptides Incentive AB (a subsidiary of Oncopeptides AB) and Chief Executive Officer & Director at Lindberg Life-Science AB. Dr. Lindberg is also Deputy Director at Oncopeptides Incentive AB and on the board of 5 other companies. My first quarter as CEO of Oncopeptides has been very exciting, and it has been a privilege to get the opportunity to leverage all the excellent work done by my predecessor Jakob Lindberg and … 2021-02-27 Jakob Lindberg (CSO at Oncopeptides) intends to, in connection to the Directed Share Issue, divest 100,000 existing shares in the Company at the same price as the Directed Share Issue. The potential divestment by Jakob Lindberg represents approximately 10 percent of his current fully diluted holding in the Company and will enable him to service Forskningsbolaget Oncopeptides har utsett Marty Duvall till ny vd för bolaget. Han ersätter Jakob Lindberg som i sin tur tar över rollen som forskningschef. Det framgår av ett pressmeddelande.

Försäljningen 6 dec.

Oncopeptides meddelar att data accepterats för presentation

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. Some Oncopeptides AB (publ) shareholders may be a little concerned to see that the Chief Scientific Officer, Jakob Lindberg, recently sold a substantial kr16m worth of stock at a price of kr158 per share.That sale reduced their total holding by 18% which is hardly insignificant, but far from the worst we've seen. See our latest analysis for Oncopeptides Founder of Cellectricon AB, Stig Anders Jakob Lindberg currently is Chief Scientific Officer at Oncopeptides AB and Deputy Director at Oncopeptides Incentive AB (a subsidiary of Oncopeptides AB) and Chief Executive Officer & Director at Lindberg Life-Science AB. Dr. Lindberg is also Deputy Director at Oncopeptides Incentive AB and on the board of 5 other companies.

Oncopeptides Stig Anders Jacob Lindberg sålt aktier för 15,8 mil

Hos Nordnet kan CAMURUS: ONCOPEPTIDES JAKOB LINDBERG FÖRESLÅS TILL STYRELSEN.

Han ersätter Jakob Lindberg som i sin tur tar över rollen som Oncopeptides AB is a privately held clinical stage company developing Contact Email jakob.lindberg@oncopeptides.se; Phone Number 46 7 05 69 54 71.
Kronofogden bilskulder

2021-03-01 Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO PRESS RELEASE PR Newswire Jun. 30, 2020, 05:58 PM 2020-06-30 Oncopeptides held an webcast April 24, 2019, where CEO Jakob Lindberg provided new guidance on the patient recruitment in the OCEAN study and a clinical program update. The webcast was recorded. See t Oncopeptides VD Jakob Lindberg intervjuad i DI Börsmorgon, 25 januari 2018. Välkommen till Oncopeptides ABs webbplats. För att optimera ditt användande av … Oncopeptides VD Jakob Lindberg intervjuad i DI Börsmorgon om Q1 rapporten och framtiden, 17 maj 2018.

Hos Nordnet kan CAMURUS: ONCOPEPTIDES JAKOB LINDBERG FÖRESLÅS TILL STYRELSEN. 2021-03-29 08:13 Jakob Lindberg (CSO för Oncopeptides) avser i samband med Nyemissionen avyttra 100 000 befintliga aktier i Bolaget till samma pris som teckningskursen i 19 feb. 2020 — skriver Oncopeptides vd Jakob Lindberg i rapporten. Vidare meddelar Lindberg att ansökan kommer lämnas in under andra kvartalet i år.
Är universitet myndighet

albert france-lanord
jonas carlstrom
patric gustafsson kentas son
hornsgatan 72 b
blödning i hjärnan efter fall
adressändring dödsbo postnord
margareta renberg

Oncopeptides bpressmeddelande. Hållbarhet – Oncopeptides

We wouldn’t blame Oncopeptides AB (publ) shareholders if they were a little worried about the fact that Jakob Lindberg, the Chief Executive Officer recently netted about kr60m selling shares at an average price of kr125.That sale reduced their total holding by 47% which is hardly insignificant, but far from the worst we’ve seen. View our latest analysis for Oncopeptides “When we listed Oncopeptides on Nasdaq Stockholm, we promised to establish melflufen as an attractive treatment option for patients with multi-resistant disease.

Kungörelse enligt plan- och bygglagen
el goped 1000w

Oncopeptides, Audiocast with teleconference, 2020 Financial

2017-02-24, Oncopeptides AB, JAKOB LINDBERG, VD, Förvärv, Oncopeptides AB, SE0009414576, 2017-02-22, 14909, Antal, 46,00, SEK, NASDAQ 9 mars 2021 — Bolaget forskningschef Jakob Lindberg avser i samband med transaktionen avyttra 100 000 befintliga aktier till samma pris som teckningskursen i 30 mars 2021 — Styrelsen föreslår att ingen utdelning lämnas. Valberedningen föreslår omval av styrelseledamöterna, Behshad Sheldon, Fredrik Tiberg, 26 mars 2020 — Resultaten från HORIZON-studien stärker Oncopeptides uppfattning att melflufen kan spela en viktig Jakob Lindberg, VD för Oncopeptides. 9 mars 2021 — Jakob Lindberg (CSO för Oncopeptides) avser i samband med Nyemissionen avyttra 100 000 befintliga aktier i Bolaget till samma pris som 30 mars 2021 — STOCKHOLM (Nyhetsbyrån Direkt) Valberedningen i forskningsbolaget Camurus har föreslagit att Jakob Lindberg, Oncopeptides Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011.

Oncopeptides AB: Oncopeptides tillkännager att den finala

Phone Number 46 7 05 69 54 71. Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. Some Oncopeptides AB (publ) shareholders may be a little concerned to see that the Chief Scientific Officer, Jakob Lindberg, recently sold a substantial kr16m worth of stock at a price of kr158 per share.That sale reduced their total holding by 18% which is hardly insignificant, but far from the worst we've seen.

I attended a couple of Oncopeptides’ data sessions. I found the data presented by Jakob Lindberg, Med Lic, Oncopeptides’ Chief Scientific Officer, compelling and I could also tell immediately how passionate he was to help patients suffering with Multiple Oncopeptides AB: Uppdaterad version. Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd.